Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Clinical Study of JTE-461 - Single and Multiple Dose Study
jRCT2071250121Phase 1Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JTE-461 in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and Pharmacokinetics. Started Jan 2026; status: recruiting.
02
Drugs
JTE-461
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2071250121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250121.